We believe that dedication to our end users, both patients and clinicians, is the key to developing lasting technological and workflow improvements to healthcare. We strive for simplicity, robustness, and intuitiveness as foundational elements of all our imaging solutions in order to delight all who touch our technology.
This shows previously unseen and information-rich cardiac activity in a subject without any contact or energization required—a feat previously reserved for Science Fiction TV and Movies. The discovery is one of many brand-new clinical insights using the body's own energy as an indicator of health. Baule and McFee's novel insights blossom into the field of biomagnetism.
Magnetocardiography’s technical and clinical development had been primarily driven by Superconducting Quantum Interference Devices (SQUID). MCG hardware has evolved steadily from single channel laboratory-based investigational devices, to high-density commercially available units.
Through always focusing on our end users and constantly scanning disciplines across science and technology, we are delivering powerful new tools to clinicians.
“We started working out of Thompson Library, the Summer of 2016. Every morning when we'd come in, we'd put a note on the window saying Yes We're Open, because we wanted to feel like a real business."
Peeyush Shrivastava, Co-Founder & CEO
Genetesis receives FDA 510(k) clearance for its cardiac imaging platform. The platform pairs the CardioFlux™ Magnetocardiograph with the integrated Faraday Analytical Cloud™ (FAC).
CardioFlux® is granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for the diagnosis of myocardial ischemia and infarction in patients with symptoms suggestive of acute coronary syndrome.
"An important step forward for patients presenting to Emergency Departments across the country with acute chest pain. Chest pain risk stratification continues to be one of our most expensive, radiation intensive, and time-consuming diagnostic burdens in the Emergency Department."
Simon A. Mahler, MD, MS, FACEP
Device is evaluated in a pilot clinical protocol studying the value of magnetocardiography in chest pain triage.
The designation represents progress for patients with suspected Coronary Microvascular Dysfunction as the FDA recognizes disease’s debilitating impacts and the lack of effective non-invasive options for efficient diagnosis.
“This milestone is a great step forward for patients who suffer from the impacts of CMD, many of whom do so unknowingly, and illustrates the FDA’s awareness that effective CMD diagnostics are largely inaccessible to most patients."
Dr. Robert Takla, MD, MBA, FACEP
If you join the team, you’ll hear over and over how we operate from “first principles”. These values are what that really means.
Meet the three founders who first saw the potential for MCG to change how patients experience cardiac care.
Co-Founder & CEO
Peeyush has 8 years of experience as a serial medical technology entrepreneur and technologist. He currently serves as the Co-Founder and Chief Executive Officer of Genetesis, where he has raised over $25 million in venture capital financing and led the company...
Co-Founder & COO
Vineet is a proven product focused executive, specializing in full lifecycle medical device development and commercial access. As Co-Founder and Chief Operations Officer of Genetesis, he is highly adept at technical and corporate strategy implementation...
Co-Founder & CTO
Emmanuel is a highly technical co-founder and technical strategist with having had a background in software development and IT operation for nearly 10 years. He currently serves as the Co-founder and Chief Technology Officer of Genetesis, where he has been responsible...
Peeyush Shrivastava
Co-Founder and CEO of Genetesis
